PeerView | Genetics

Free CME from PeerView

Genetics CME

Credits: 2.0 CME / MOC

Purdue University

Accelerating Progress in the Treatment of Alzheimer’s Disease: How Can We Achieve Timely and Accurate Neuropathological Diagnosis and Precision Management of Mild Cognitive Impairment in Early Alzheimer’s Disease?

Liana G. Apostolova, MS, MD, FAAN

April 20, 2022

Credits: 0.5 CME / NCPD

Medical Learning Institute, Inc.

Breakthroughs in Spinal Muscular Atrophy: Managing the Life-Changing Impact of Gene Replacement Therapy

Julie Parsons, MD

March 01, 2022

Credits: 0.5 CME

PVI, PeerView Institute for Medical Education

Putting the Pieces Together: Would You Recognize Acute Hepatic Porphyria If You Saw It?

Herbert L. Bonkovsky, MD

February 25, 2022

Credits: 1 CME / MOC / NCPD / CPE

PVI, PeerView Institute for Medical Education

Making New Strides in Hypertrophic Cardiomyopathy: The Latest Guidelines, Science, and Strategies for Early Diagnosis and Tailored Treatment

Neal K. Lakdawala, MD / Anjali Tiku Owens, MD

November 13, 2021

Credits: 1 CME / MOC / CC

Medical Learning Institute, Inc.

Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC: Refining and Expanding Best Practices in Advanced and Early-Stage Disease Settings

Lynette M. Sholl, MD

October 29, 2021

Credits: 0.5 CME

Medical Learning Institute, Inc.

On the Cusp of a New Targeted Treatment Era in ALS: Exploring the Emerging Therapeutic Landscape

Professor Dame Pamela J. Shaw

October 22, 2021

Credits: 1.00 CME / MOC / NCPD / CPE

Heart Failure Society of America

Easing the Burden of Hypertrophic Cardiomyopathy: Progress in Understanding and Addressing Its Pathophysiology

Daniel Jacoby, MD

October 01, 2021

Medical Learning Institute, Inc.

Target Practice: Understanding How PARP Inhibitors Take Aim at DNA Damage Response Mutations Across Solid Tumors

Susana Banerjee, MBBS, MA, FRCP, PhD

May 07, 2021

Medical Learning Institute, Inc.

Acute Hepatic Porphyria: Disease Diagnosis and Revelations Regarding the Role of siRNA Therapy

Karl E. Anderson, MD

April 15, 2021

Medical Learning Institute, Inc.

New Milestones and Changing Standards of Care in EGFR-Mutated NSCLC: Expanding the Benefits of Genomic Testing and EGFR-Targeted Therapy to Early-Stage Lung Cancer

March 09, 2021

Medical Learning Institute, Inc.

Targeting DNA Repair Defects Through PARP Inhibition in Prostate Cancer: Rationale, Evidence, and Clinical Implications

Emmanuel S. Antonarakis, MD

July 22, 2020

Medical Learning Institute, Inc.

Assessing the Potential Role of Emerging Therapies in the Early Diagnosis and Optimal Management of Chronic Visceral Acid Sphingomyelinase Deficiency

Robin Lachmann, MD, PhD / Melissa Wasserstein, MD

June 03, 2020

Medical Learning Institute, Inc.

Targeting Pathogenic Mutations in the DNA Damage Response Pathway: Genetic Testing and Counseling in the Era of Precision Medicine and Next-Generation Sequencing

Mike Janicek, MD / Bradley J. Monk, MD / FACS, FACOG

May 27, 2020